{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T12:02:39Z","timestamp":1785067359836,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,26]]},"DOI":"10.7759\/cureus.113391","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T11:56:28Z","timestamp":1785066988000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors"],"prefix":"10.7759","author":[{"given":"Safiah","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson O","family":"Oyibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/mgmj.mgmj_386_24","article-title":"A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus","volume":"12","author":"Dsouza PD","year":"2025","unstructured":"Dsouza PD, Chitralu SPP, Khan R, Nayamagoud SB. Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus. MGM J Med Sci. 2025, 12:136-46. 10.4103\/mgmj.mgmj_386_24","journal-title":"MGM J Med Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01992-4","article-title":"Tirzepatide: a review in type 2 diabetes","volume":"84","author":"France NL","year":"2024","unstructured":"France NL, Syed YY. Tirzepatide: a review in type 2 diabetes. Drugs. 2024, 84:227-38. 10.1007\/s40265-023-01992-4","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang MH","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024, 7:e2427258. 10.1001\/jamanetworkopen.2024.27258","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra R","year":"2023","unstructured":"Mishra R, Raj R, Elshimy G, et al.. Adverse events related to tirzepatide. J Endocr Soc. 2023, 7:bvad016. 10.1210\/jendso\/bvad016","journal-title":"J Endocr Soc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12420","article-title":"Disorders of calcium metabolism: hypocalcemia and hypercalcemia","volume":"13","author":"Tinawi M","year":"2021","unstructured":"Tinawi M. Disorders of calcium metabolism: hypocalcemia and hypercalcemia. Cureus. 2021, 13:e12420. 10.7759\/cureus.12420","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05910809","article-title":"Calcium metabolism in health and disease","volume":"5 Suppl 1","author":"Peacock M","year":"2010","unstructured":"Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010, 5 Suppl 1:S23-30. 10.2215\/CJN.05910809","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy054","article-title":"Hypercalcemia: etiology and management","volume":"33","author":"Renaghan AD","year":"2018","unstructured":"Renaghan AD, Rosner MH. Hypercalcemia: etiology and management. Nephrol Dial Transplant. 2018, 33:549-51. 10.1093\/ndt\/gfy054","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.936204","article-title":"Unusual case of dehydration leading to severe symptomatic hypercalcemia","volume":"23","author":"Kc O","year":"2022","unstructured":"Kc O, Dahal PH, Koirala M, Al Zaghal E. Unusual case of dehydration leading to severe symptomatic hypercalcemia. Am J Case Rep. 2022, 23:e936204. 10.12659\/AJCR.936204","journal-title":"Am J Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2025-266308","article-title":"Familial hypocalciuric hypercalcaemia type 1 due to a rare CASR missense mutation: a delayed diagnosis in a man with chronic hypercalcaemia","volume":"18","author":"Mon HY","year":"2025","unstructured":"Mon HY, Win NN, Oyibo SO. Familial hypocalciuric hypercalcaemia type 1 due to a rare CASR missense mutation: a delayed diagnosis in a man with chronic hypercalcaemia. BMJ Case Rep. 2025, 18:e266308. 10.1136\/bcr-2025-266308","journal-title":"BMJ Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2023.0228","article-title":"Thiazide diuretics and primary hyperparathyroidism","volume":"84","author":"Mifsud S","year":"2023","unstructured":"Mifsud S, Montanaro G, Craus S, Mifsud EL, Gruppetta M. Thiazide diuretics and primary hyperparathyroidism. Br J Hosp Med (Lond). 2023, 84:1-8. 10.12968\/hmed.2023.0228","journal-title":"Br J Hosp Med (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00180287","article-title":"Subacute effects of thiazide administration on renal hemodynamics and calcium metabolism","volume":"70","author":"Nowack R","year":"1992","unstructured":"Nowack R, H\u00f6fner MC, Reichel H, Schmidt-Gayk H, Ritz E. Subacute effects of thiazide administration on renal hemodynamics and calcium metabolism. Clin Investig. 1992, 70:686-91. 10.1007\/BF00180287","journal-title":"Clin Investig"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20213210S1148a","article-title":"Liraglutide-induced hypercalcemia with AKI: PO0320","volume":"32","author":"Patel N","year":"2021","unstructured":"Patel N, Shahzad MA, Whittier WL. Liraglutide-induced hypercalcemia with AKI: PO0320. J Am Soc of Nephrol. 2021, 32:148. 10.1681\/ASN.20213210S1148a","journal-title":"J Am Soc of Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-25-0067","article-title":"A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use","volume":"2025","author":"Nduma B","year":"2025","unstructured":"Nduma B, Malapati SN, Vibhuti V. A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use. Endocrinol Diabetes Metab Case Rep. 2025, 2025:e250067. 10.1530\/EDM-25-0067","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.108061","article-title":"Hypercalcemia induced by tirzepatide and calcium supplementation: a case report","volume":"18","author":"Nguyen E","year":"2026","unstructured":"Nguyen E, Kawamura M, Munoz I, Ahn G. Hypercalcemia induced by tirzepatide and calcium supplementation: a case report. Cureus. 2026, 18:e108061. 10.7759\/cureus.108061","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.12746\/swjm.v14i58.1641","article-title":"A rare metabolic complication: hypercalcemic crisis in a patient using a GLP-1 agonist","volume":"14","author":"Dushime J","year":"2026","unstructured":"Dushime J, Ahmad S. A rare metabolic complication: hypercalcemic crisis in a patient using a GLP-1 agonist. Southwest J Med. 2026, 14:74-6. 10.12746\/swjm.v14i58.1641","journal-title":"Southwest J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517595-a-case-of-severe-hypercalcemia-in-a-patient-taking-tirzepatide-potential-risk-factors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T11:56:28Z","timestamp":1785066988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517595-a-case-of-severe-hypercalcemia-in-a-patient-taking-tirzepatide-potential-risk-factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.113391","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,26]]}}}